Lexicon Pharmaceuticals (NASDAQ:LXRX) Upgraded to “Sell” by StockNews.com

Lexicon Pharmaceuticals (NASDAQ:LXRX) was upgraded by stock analysts at StockNews.com to a “sell” rating in a research report issued to clients and investors on Monday.

Separately, Needham & Company LLC reaffirmed a “hold” rating on shares of Lexicon Pharmaceuticals in a report on Thursday.

Lexicon Pharmaceuticals Price Performance

NASDAQ:LXRX traded down $0.10 during midday trading on Monday, hitting $1.87. The company had a trading volume of 3,490,098 shares, compared to its average volume of 4,476,207. The company has a market capitalization of $460.47 million, a PE ratio of -2.34 and a beta of 1.27. The company has a quick ratio of 5.58, a current ratio of 5.60 and a debt-to-equity ratio of 1.07. Lexicon Pharmaceuticals has a 52-week low of $0.92 and a 52-week high of $3.79. The stock’s fifty day moving average price is $2.41 and its 200-day moving average price is $1.69.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last announced its quarterly earnings data on Monday, March 11th. The biopharmaceutical company reported ($0.20) EPS for the quarter, beating the consensus estimate of ($0.23) by $0.03. The firm had revenue of $0.70 million for the quarter, compared to analyst estimates of $0.68 million. Lexicon Pharmaceuticals had a negative return on equity of 138.54% and a negative net margin of 14,573.20%. As a group, research analysts expect that Lexicon Pharmaceuticals will post -0.71 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of LXRX. Cantor Fitzgerald L. P. purchased a new stake in shares of Lexicon Pharmaceuticals in the 4th quarter worth about $25,000. Bank of Montreal Can bought a new stake in Lexicon Pharmaceuticals during the 1st quarter valued at approximately $26,000. TIAA Trust National Association purchased a new position in shares of Lexicon Pharmaceuticals during the 3rd quarter worth approximately $29,000. Kestra Advisory Services LLC bought a new position in shares of Lexicon Pharmaceuticals in the 2nd quarter worth approximately $33,000. Finally, Principal Securities Inc. purchased a new position in shares of Lexicon Pharmaceuticals in the 4th quarter valued at approximately $33,000. Institutional investors own 74.70% of the company’s stock.

About Lexicon Pharmaceuticals

Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract.